Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS Secretary McClellan?

This article was originally published in The Gray Sheet

Executive Summary

Tommy Thompson will step down from the HHS secretary spot Feb. 4 or when a successor is named, he announces Dec. 3. CMS Administrator Mark McClellan, MD/PhD, and HHS Deputy Secretary Claude Allen, JD, are considered leading contenders to replace him. Thompson also mentioned CDC Director Julie Gerberding, MD/MPH; NIH Director Elias Zerhouni, MD; and National Institute of Allergy & Infectious Diseases DirectorAnthony Fauci, MD, as possible successors. The search has moved outside the department, with some state governors reportedly interviewed; former Speaker of the House Newt Gingrich also has voiced interest. Although not discounting a future role in public service, Thompson said that after 38 years he is ready to enter the private sector. He lauded HHS' work on the Medicare Modernization Act, while conceding he "would like to have had the opportunity to negotiate" its details...

You may also be interested in...



HHS Secretary-Designate Leavitt’s Record Suggests Tech-Friendly Outlook

Former Utah Governor and current Environmental Protection Agency Administrator Michael Leavitt brings to the HHS secretary post a pro-business, pro-innovation record that could bode well for med tech firms

Second EU MDR Notified Body Designated In France

Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.

Takeda, Astellas Found New JV To Support Japanese Bioventures

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel